Literature DB >> 15094181

Prognostic factors of small cell lung cancer.

Gianfranco Buccheri1, Domenico Ferrigno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15094181     DOI： 10.1016/j.hoc.2003.12.011

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


× No keyword cloud information.
  7 in total

1.  Clinical significance of plasma fibrinogen and D-dimer in predicting the chemotherapy efficacy and prognosis for small cell lung cancer patients.

Authors:  L-R Zhu; J Li; P Chen; Q Jiang; X-P Tang
Journal:  Clin Transl Oncol       Date:  2015-07-17       Impact factor: 3.405

2.  Prognostic significance of the lymphocyte-to-monocyte ratio in patients with small cell lung cancer.

Authors:  Se-Il Go; Rock Bum Kim; Haa-Na Song; Myoung Hee Kang; Un Seok Lee; Hye Jung Choi; Seung Jun Lee; Yu Ji Cho; Yi Yeong Jeong; Ho Cheol Kim; Jong Deog Lee; Seok-Hyun Kim; Jung-Hun Kang; Hui Ling; Gyeong-Won Lee
Journal:  Med Oncol       Date:  2014-11-23       Impact factor: 3.064

3.  Small-cell lung cancer: 8 years experience of a single multidisciplinary team.

Authors:  Loaie M El-Helw; Trevor K Rogers; Matthew Q F Hatton
Journal:  J Oncol       Date:  2008-10-16       Impact factor: 4.375

4.  Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer.

Authors:  Soojung Hong; Young Ae Kang; Byoung Chul Cho; Dae Joon Kim
Journal:  Yonsei Med J       Date:  2012-01       Impact factor: 2.759

5.  The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer.

Authors:  M H Kang; S-I Go; H-N Song; A Lee; S-H Kim; J-H Kang; B-K Jeong; K M Kang; H Ling; G-W Lee
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

6.  High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.

Authors:  Dan Liu; Yi Huang; Lei Li; Juan Song; Li Zhang; Weimin Li
Journal:  BMC Cancer       Date:  2017-12-21       Impact factor: 4.430

7.  Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer.

Authors:  S Baka; R Califano; R Ferraldeschi; L Aschroft; N Thatcher; P Taylor; C Faivre-Finn; F Blackhall; P Lorigan
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.